JP7074750B2 - カルバモイルフェニルアラニノール化合物およびその使用 - Google Patents

カルバモイルフェニルアラニノール化合物およびその使用 Download PDF

Info

Publication number
JP7074750B2
JP7074750B2 JP2019518480A JP2019518480A JP7074750B2 JP 7074750 B2 JP7074750 B2 JP 7074750B2 JP 2019518480 A JP2019518480 A JP 2019518480A JP 2019518480 A JP2019518480 A JP 2019518480A JP 7074750 B2 JP7074750 B2 JP 7074750B2
Authority
JP
Japan
Prior art keywords
substituted
pharmaceutical composition
compound
carbon atoms
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019518480A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503246A (ja
JP2020503246A5 (enExample
Inventor
フィオン ハーレー
ローレンス パトリック カーター
Original Assignee
ジャズ ファーマスティカルズ アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジャズ ファーマスティカルズ アイルランド リミテッド filed Critical ジャズ ファーマスティカルズ アイルランド リミテッド
Publication of JP2020503246A publication Critical patent/JP2020503246A/ja
Publication of JP2020503246A5 publication Critical patent/JP2020503246A5/ja
Application granted granted Critical
Publication of JP7074750B2 publication Critical patent/JP7074750B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/66—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/58—Y being a hetero atom
    • C07C275/60—Y being an oxygen atom, e.g. allophanic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2019518480A 2016-10-06 2017-10-06 カルバモイルフェニルアラニノール化合物およびその使用 Active JP7074750B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404917P 2016-10-06 2016-10-06
PCT/US2017/055598 WO2018067971A1 (en) 2016-10-06 2017-10-06 Carbamoyl phenylalaninol compounds and uses therof

Publications (3)

Publication Number Publication Date
JP2020503246A JP2020503246A (ja) 2020-01-30
JP2020503246A5 JP2020503246A5 (enExample) 2020-10-22
JP7074750B2 true JP7074750B2 (ja) 2022-05-24

Family

ID=60183122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019518480A Active JP7074750B2 (ja) 2016-10-06 2017-10-06 カルバモイルフェニルアラニノール化合物およびその使用

Country Status (11)

Country Link
US (5) US10710958B2 (enExample)
EP (2) EP4316592B1 (enExample)
JP (1) JP7074750B2 (enExample)
KR (1) KR102616545B1 (enExample)
CN (1) CN110049966A (enExample)
CA (1) CA3039045A1 (enExample)
ES (1) ES2964943T3 (enExample)
MY (1) MY202185A (enExample)
PH (1) PH12019500751A1 (enExample)
SG (1) SG11201903076QA (enExample)
WO (1) WO2018067971A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
SG11202000817SA (en) 2017-07-31 2020-02-27 Jazz Pharmaceuticals Ireland Ltd Carbamoyl phenylalaninol analogs and uses thereof
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518921A (ja) 2004-10-28 2008-06-05 エスケー ホルディングス カンパニー リミテッド うつ病のための補助療法
JP2008545795A (ja) 2005-06-08 2008-12-18 アブダラー アーナオウ 睡眠覚醒障害の治療
JP2008546778A (ja) 2005-06-22 2008-12-25 エスケー ホルディングス カンパニー リミテッド 性機能障害を治療する方法
JP2012530779A (ja) 2009-06-22 2012-12-06 エスケー バイオファーマシューティカルズ カンパニー リミテッド 疲労を治療又は予防するための方法
JP2012531405A (ja) 2009-06-26 2012-12-10 エスケー バイオファーマシューティカルズ カンパニー リミテッド 薬物嗜癖の治療および嗜癖関連行動を改善するための組成物
JP2013510142A (ja) 2009-11-06 2013-03-21 エスケー バイオファーマスティカルズ カンパニー リミテッド 線維筋痛症候群の治療方法
JP2013531008A (ja) 2010-06-30 2013-08-01 エスケー バイオファーマシューティカルズ カンパニー リミテッド 下肢静止不能症候群を治療する方法
JP2013533253A (ja) 2010-06-30 2013-08-22 エスケー バイオファーマシューティカルズ カンパニー リミテッド 双極性障害を治療する方法
JP2016512531A (ja) 2013-03-13 2016-04-28 エアリアル，バイオファーマ，エルエルシー カタプレキシーの治療
JP2016532679A (ja) 2013-07-18 2016-10-20 ジャズ ファーマスティカルズ インターナショナル スリー リミテッドＪａｚｚ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｉｉ Ｌｉｍｉｔｅｄ 肥満の治療
JP2017512211A (ja) 2014-02-28 2017-05-18 エスケー バイオファーマスティカルズ カンパニー リミテッド アミノカルボニルカルバメート化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
WO2000038672A2 (en) 1998-12-23 2000-07-06 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
CN105848650A (zh) 2013-07-12 2016-08-10 爵士制药国际Iii有限公司 促进吸烟停止
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518921A (ja) 2004-10-28 2008-06-05 エスケー ホルディングス カンパニー リミテッド うつ病のための補助療法
JP2008545795A (ja) 2005-06-08 2008-12-18 アブダラー アーナオウ 睡眠覚醒障害の治療
JP2008546778A (ja) 2005-06-22 2008-12-25 エスケー ホルディングス カンパニー リミテッド 性機能障害を治療する方法
JP2012530779A (ja) 2009-06-22 2012-12-06 エスケー バイオファーマシューティカルズ カンパニー リミテッド 疲労を治療又は予防するための方法
JP2012531405A (ja) 2009-06-26 2012-12-10 エスケー バイオファーマシューティカルズ カンパニー リミテッド 薬物嗜癖の治療および嗜癖関連行動を改善するための組成物
JP2013510142A (ja) 2009-11-06 2013-03-21 エスケー バイオファーマスティカルズ カンパニー リミテッド 線維筋痛症候群の治療方法
JP2013531008A (ja) 2010-06-30 2013-08-01 エスケー バイオファーマシューティカルズ カンパニー リミテッド 下肢静止不能症候群を治療する方法
JP2013533253A (ja) 2010-06-30 2013-08-22 エスケー バイオファーマシューティカルズ カンパニー リミテッド 双極性障害を治療する方法
JP2016512531A (ja) 2013-03-13 2016-04-28 エアリアル，バイオファーマ，エルエルシー カタプレキシーの治療
JP2016532679A (ja) 2013-07-18 2016-10-20 ジャズ ファーマスティカルズ インターナショナル スリー リミテッドＪａｚｚ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｉｉ Ｌｉｍｉｔｅｄ 肥満の治療
JP2017512211A (ja) 2014-02-28 2017-05-18 エスケー バイオファーマスティカルズ カンパニー リミテッド アミノカルボニルカルバメート化合物

Also Published As

Publication number Publication date
US11149000B2 (en) 2021-10-19
PH12019500751A1 (en) 2019-08-05
SG11201903076QA (en) 2019-05-30
WO2018067971A1 (en) 2018-04-12
EP4316592A2 (en) 2024-02-07
EP4316592B1 (en) 2026-08-12
EP3523275B1 (en) 2023-09-27
KR20190072561A (ko) 2019-06-25
JP2020503246A (ja) 2020-01-30
EP4316592A3 (en) 2024-05-01
US20190218175A1 (en) 2019-07-18
US10710958B2 (en) 2020-07-14
US20240018098A1 (en) 2024-01-18
US11780805B2 (en) 2023-10-10
KR102616545B1 (ko) 2023-12-26
EP3523275A1 (en) 2019-08-14
ES2964943T3 (es) 2024-04-10
US20200290955A1 (en) 2020-09-17
CN110049966A (zh) 2019-07-23
US20220098145A1 (en) 2022-03-31
MY202185A (en) 2024-04-15
CA3039045A1 (en) 2018-04-12
US20250059136A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
US11780805B2 (en) Carbamoyl phenylalaninol compounds and uses thereof
JP7642707B2 (ja) カルバモイルフェニルアラニノール類縁体およびその使用
US12312328B2 (en) Pyrazoline dihydroquinolones, pharmaceutical compositions, and uses
ES2261234T5 (es) Metabolitos de bupropion y metodos de sintesis y uso.
US20250032442A1 (en) Methods and compositions for treating cognitive impairment
CA3232827A1 (en) Substituted phenylalkylamines
JP2021504303A (ja) Ｃｎｓ疾患を治療するためのアミノアダマンチルナイトレート化合物およびそれらの使用
CA3229907A1 (en) Deuterated empathogens
CN121568919A (zh) 不对称苯烷基胺
HK40003964A (en) Carbamoyl phenylalaninol compounds and uses therof
CA3034885A1 (en) Hydroxynorketamine derivatives for the treatment of disorders
CN111094259A (zh) 止痛化合物
CA3229910A1 (en) Fluorinated empathogens
WO2024182774A1 (en) Deuterated and fluorinated empathogens
CN121127458A (zh) 苯烷胺前药
HK40106138A (en) Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20191211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200911

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220422

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220512

R150 Certificate of patent or registration of utility model

Ref document number: 7074750

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250